- Noribogaine
- O-Desmethylibogaine
- 12-Hydroxyibogamine
- Ibogamin-12-ol
- 7-Ethyl-6,6a,7,8,9,10,12,13-octahydro-5H-6,9-methanopyrido[1′,2′:1,2]azepino[4,5-b]indol-2-ol
Shulgin, AT. Basic Pharmacology and Effects In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.
Wasko, M; Witt-Enderby, PA; Surratt, CK. DARK classics in chemical neuroscience: Ibogaine ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2475–2483. 5.1 MB. https://doi.org/10.1021/acschemneuro.8b00294 #Noribogaine
Iyer, RN; Favela, D; Zhang, G; Olson, DE. The iboga enigma: The chemistry and neuropharmacology of iboga alkaloids and related analogs Nat. Prod. Rep., 14 Aug 2020, 38 (2), 307-329. 3.3 MB. https://doi.org/10.1039/D0NP00033G #2
Cameron, LP; Tombari, RJ; Lu, J; Pell, AJ; Hurley, ZQ; Ehinger, Y; Olson, DE. A non-hallucinogenic psychedelic analogue with therapeutic potential Nature, 1 Jan 2021, 589 (7842), 474–479. 10.5 MB. https://doi.org/10.1038/s41586-020-3008-z #Noribogaine MS,NMR,IR
Cumming, P; Scheidegger, M; Dornbierer, D; Palner, M; Quednow, BB; Martin-Soelch, C. Molecular and functional imaging studies of psychedelic drug action in animals and humans Molecules, 1 Jan 2021, 26 (9), 2451. 3.5 MB. https://doi.org/10.3390/molecules26092451 #18